Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662764 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
A Phase 3 study of Moderate-to-severe Acute Pain, sponsored by Talphera.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 11
- Study locations
NCT02662764 is a Phase 3 study of Moderate-to-severe Acute Pain that has completed, run by Talphera. The registered enrollment target is 320 participants. The trial reports 11 study locations across 6 states.
The verdict
NCT02662764, a Phase 3 study of Moderate-to-severe Acute Pain, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 11
- Study locations
Study Summary
Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg
Conditions Studied
Interventions
- DRUG Zalviso™ 15 mcg
Study Locations (11)
Florida
- Gulfcoast Research Associates - Sarasota
- G&G Research - Vero Beach
- Orthopedic Center of Vero Beach - Vero Beach
- Visions Clinical Research - Wellington
Alabama
- Eliza Coffee Memorial Hospital - Florence
- Shoals Medical Trials - Sheffield
Texas
- Westside Surgical Hospital - Houston
- Hermann Drive Surgical Hospital - Houston
Arizona
- Arizona Research Center - Phoenix
Georgia
- Southeastern Center for Clinical Trials - Decatur
Utah
- Jean Brown Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2017-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02662764
The ClinicalTrials.gov registry entry for NCT02662764 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate-to-severe Acute Pain appearing as the primary indexed condition, and to 1 intervention - of which Zalviso™ 15 mcg is the first listed.
NCT02662764 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Florida, Alabama, Texas.
Frequently Asked Questions
What is clinical trial NCT02662764 about?
NCT02662764 is a clinical study titled "Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg". Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg
What is the current status of trial NCT02662764?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2016-09-28. Estimated completion is 2017-05-05.
What conditions does trial NCT02662764 study?
This clinical trial studies the following conditions: Moderate-to-severe Acute Pain.
What interventions are being tested in trial NCT02662764?
The interventions under investigation include: Zalviso™ 15 mcg (DRUG).
Who is sponsoring clinical trial NCT02662764?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02662764 being conducted?
This trial has 11 study locations across Alabama, Arizona, Florida, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.